Pelvic Floor Muscle Training With a Digital Therapeutic Device to Standard Exercises for Stress Urinary Incontinence
NCT ID: NCT04508153
Last Updated: 2021-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
369 participants
INTERVENTIONAL
2020-10-01
2021-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) compared to standard care of a PFM exercise home program (Kegel arm) for the treatment of SUI or SMUI.
* Following completion of e-consent and screening, including an initial bladder diary and introductory phone call to review the study requirements, subjects are considered officially enrolled.
* A series of baseline assessments will be administered to all subjects to evaluate symptom severity, frequency and impact.
* Subjects will then be randomized to either the leva® arm or Kegel arm on a 1 to 1 ratio using block randomization. Prior to initiation of the trial, a randomization sequence will be generated by the ObvioHealth system. Participants will be automatically allocated the next available slot in the sequence at the time of their randomization and assigned to the leva® or Kegel group accordingly.
* Prior to beginning the program, subjects in the Kegel arm will receive printed instructions for PFMT with Kegel exercises. Subjects in the leva® arm will be shipped the leva® digital device, along with instructions for use and how to download the corresponding digital app. Day 1 of the study begins the day following receipt of materials.
* Study population: women with SUI or SMUI.
* The study requires no office visits. All participant data will be entered in the subject's smartphone using a custom designed mobile application. Participants will be able to interact with the app throughout the study period and will be presented with surveys and a voiding diary on a specified schedule during an 8-week treatment period. There will also be expected post-intervention follow up surveys at 6- and 12-months
* Using virtual recruiting, a total of up to 350 subjects will be enrolled in the trial.
* Subjects in both arms will have three scheduled phone calls with study staff during the first two weeks of treatment.
* Subjects can speak to the study staff at any time via an in-app chat function, the phone, or videoconference.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Leva PDHS arm
Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.
Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks.
Leva Pelvic Digital Health System
Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
Kegel arm
Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
Kegel exercises
Pelvic floor muscle training (PFMT), commonly referred to as "Kegel" exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Leva Pelvic Digital Health System
Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
Kegel exercises
Pelvic floor muscle training (PFMT), commonly referred to as "Kegel" exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of giving informed consent
* Possess a smartphone capable of interacting with the ObvioHealth and Renovia apps
* Self-reported SUI/SMUI symptoms of ≥ three months duration
* Diagnosis SMUI based on Medical, Epidemiologic and Social Aspects of Aging (MESA) stress symptom score (Percent of total possible stress score) greater than MESA urge symptom score (percent of total possible urge score)
* English speaking
* Postmenopausal, post hysterectomy, or willing to use an acceptable method of birth control for the duration of the study
* Able to complete a bladder diary using the ObvioHealth app
* Able to complete electronic surveys and upload data
* Willing to provide contact information and respond to remote contact: phone calls, text messages, email
* Willing to participate in the 8-week study with follow up at 6-and 12-months, refraining from the pursuit of treatment for Stress UI using other modalities (i.e. will not wear a pessary, participate in pelvic floor Physical Therapy or surgery) during the first 8 weeks
Exclusion Criteria
* Reports seeing or feeling a vaginal bulge or sensation of vaginal bulge
* Diagnosis of any neuromuscular disease that may contribute to UI (i.e., multiple sclerosis, spinal cord injury, Parkinson's Disease, etc.)
* Non-ambulatory, per patient report
* Currently pregnant or \<6 months post-partum per patient report
* Currently (or within the last 1 month) breast feeding
* Prior surgery for stress UI
* Previous PFMT: 2 visits within the last 3 months under a supervised therapeutic plan of care
* Currently taking, or has taken within the last 2 months, medication to treat UI
* Prior augmentation cystoplasty or artificial sphincter
* Implanted nerve stimulator for urinary symptoms, active within the past 60 days
* Participation in another clinical study within 30 days of screening
* Impaired cognitive function per patient report and evaluation of medication list
* Contraindication to the use of a vaginal probe
* Unable to understand instructions on the use of the leva® PDHS
* Unable to operate a smartphone app with use of Bluetooth and Wi-Fi connectivity
18 Years
100 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OBVIO HEALTH USA, Inc.
UNKNOWN
University of Alabama at Birmingham
OTHER
Renovia, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Holly Richter, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Milena Weinstein, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Gena Dunnivan, MD
Role: PRINCIPAL_INVESTIGATOR
University of New Mexico
Noelani M Guaderrama, MD
Role: PRINCIPAL_INVESTIGATOR
Southern California Permanentae
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama *** Virtual Trial May be enrolled from any US Location
Birmingham, Alabama, United States
Southern California Permanente Medical Group*** Virtual Trial May be enrolled from any US Location
Irvine, California, United States
University of New Mexico *** Virtual Trial May be enrolled from any US Location
Albuquerque, New Mexico, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weinstein MM, Dunivan GC, Guaderrama NM, Richter HE. Digital Therapeutic Device for Urinary Incontinence: A Longitudinal Analysis at 6 and 12 Months. Obstet Gynecol. 2023 Jan 1;141(1):199-206. doi: 10.1097/AOG.0000000000005036. Epub 2022 Nov 30.
Weinstein MM, Dunivan G, Guaderrama NM, Richter HE. Digital Therapeutic Device for Urinary Incontinence: A Randomized Controlled Trial. Obstet Gynecol. 2022 Apr 1;139(4):606-615. doi: 10.1097/AOG.0000000000004725. Epub 2022 Mar 10.
Weinstein MM, Pulliam SJ, Richter HE. Randomized trial comparing efficacy of pelvic floor muscle training with a digital therapeutic motion-based device to standard pelvic floor exercises for treatment of stress urinary incontinence (SUV trial): An all-virtual trial design. Contemp Clin Trials. 2021 Jun;105:106406. doi: 10.1016/j.cct.2021.106406. Epub 2021 Apr 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBVIO-REN-001
Identifier Type: -
Identifier Source: org_study_id